The Phase 3 trial from Merck and Moderna will investigate the safety and efficacy of mRNA vaccine V940 in combination with Keyturda in melanoma patients.
Biotech star Moderna seeks next success after COVID vaccine bostonglobe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bostonglobe.com Daily Mail and Mail on Sunday newspapers.
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe DMFS results